LOXL2 and pancreatic ductal adenocarcinoma: Contradictorily, in pancreatic ductal adenocarcinoma, decreasing ECM with an anti-LOXL2 antibody in vivo boosted tumor growth and diminished overall survival, suggesting a protective role of ECM (20).